- Recruiting
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Updated: Sep 29, 2022
GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT05431608
Official Title: Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : June 24, 2022
Click here for details on ClinicalTrials.gov
GPRC5D-Targeted CAR T Cell MCARH109
Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109 (Code C176222)
Autologous Anti-GPRC5D CAR-T Cells MCARH109
Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109
Autologous GPRC5D-targeted CAR T Cells MCARH109
MCARH 109
MCARH-109
MCARH109
BCMA-Targeted CAR T Cell MCARH125
Biological: MCARH125
Biological: MCARH109
- New York: Memorial Sloan-Kettering Cancer Center New York
Location
United States, New York
RELATED GPRC5D POSTS
NCT04555551: Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma